

In Pursuit of Your Success



News & Updates

BIO International Convention Returns to San Diego

"San Diego's booming innovation economy is leading the way on everything from drones to genomes," San Diego Mayor Kevin Faulconer said. "That's why San Diego is the perfect host city for BIO

2017 this June - a convention that brings together biotech industry leaders from around the world to showcase the exciting discoveries being made in life sciences."

San Diego continues to be one of the top biotech clusters in the U.S. and a leader in genomics and digital health. The region is home to more than 1,100 life



sciences companies, including **BioDuro**, and more than 86 independent and university-affiliated research institutes.

Faulconer said BIO 2017 is likely to attract 16,000 registrants and 2,200 companies, including 40 percent from other countries.

Beyond the expected 16,000 attendees from 76 nations, **BIO 2017** will host more than 1,800 exhibitors. The exhibit floor will feature product focus zones including the Innovation Zone, Digital Health Zone, Start-Up Stadium and BIO Talent Connect. This is the third time in the past nine years BIO is being held in San Diego.



ChinaBio Partnering Forum 2017

BioDuro joined ChinaBio Partnering Forum as a Silver Sponsor for two days of productive partnering in Zhuhai, China. The event, held over May 31-June 1, attracted biotech and pharma leaders from more than 460 companies and at least 22 countries, making it the largest partnering conference in China.

Support and funding available in China continues to be leveraged by Western and China companies in order to develop assets more cost effectively and efficiently. 2016 was another record-setting year in VC funds raised (\$15B) and invested (\$5.8B) into life science in China. Partnering activity continues to be robust, with over \$8B in deal value created in 2015 and 2016.

Ian Wisenberg, Chief Financial Officer at BioDuro,

participated in a panel discussion on funding drug development in China through VC and partnerships, and based on needs, which types of partnerships are the best financial and strategic fits.

In addition to the ability to provide a fully integrated **Drug Discovery** and **Development** program, up to the Clinical Candidate stage (and in some cases beyond, including CMC), BioDuro's keen interest in the topic was fostered by the rapidly paced growth of discovery and development of innovative drugs in China.

BioDuro Shanghai wins Best Innovation Practice Award

On April 20, 2017, BioDuro Shanghai was awarded with "Best Innovation Practice" at the 2017 Shanghai Free Trade Zone business conference.

A total of 37,000 companies participated in the conference. With its strong science research capability, state of the art facilities and professional services, BioDuro Shanghai successfully stands out of that crowd with 200 other outstanding companies.

Below, Cyrus K. Mirsaidi, President and CEO of BioDuro, is shown receiving the award on behalf of the company.



Immunology and Inflammatory Disease Models

BioDuro's pharmacology team has extensive drug discovery and development experience in the pharmaceutical industry enabling us to support fully integrated programs, including study design and data interpretation. Special expertise in metabolic and inflammatory diseases is coupled with a commitment to working with clients to develop customized models for rare diseases.

Multiple Sclerosis:

Experimental Autoimmune Encephalomyelitis (EAE) Models

[View Data](#)

Rheumatoid Arthritis Models:

Rodent collagen-induced arthritis (CIA) models

[View Data](#)

Inflammatory Bowel Disease (IBD):
Dextran Sulfate Sodium (DSS)-Induced Colitis Model

[View Data](#)

Dermatitis:
Delayed-Type Hypersensitivity (DTH) Model

[View Data](#)

FITC Induced Dermatitis Model

[View Data](#)

Systemic Lupus Erythematosus (SLE):
Pristane Induced Lupus Model

[View Data](#)

MRL/lpr Genetic Lupus Model

[View Data](#)

Autoimmune Hepatitis (AIH):
CON A -Induced Hepatitis Model

[View Data](#)

Psoriasis:
Imiquimod-Induced Psoriasis Model

[View Data](#)

Asthma:
Ovalbumin (OVA)-Induced Allergic Asthma Model

[View Data](#)

Sepsis:
LPS-Induced Cytokine Secretion Model

[View Data](#)

Our pharmacology team has successfully collaborated with large pharmaceutical companies and numerous small companies. The success of these collaborations is highlighted by the quality data provided that have informed key project decisions and regulatory filings. Beyond providing analysis, our senior team's expertise allows for the development of a consulting relationship with client partners.

[Request a Study Proposal](#)

Events

World Preclinical Congress

June 12-16, 2017

Boston, MA

Booth #204

[Schedule a Meeting](#)

BIO 2017 International Convention

June 19-22, 2017

San Diego, CA

[Request a BioDuro Reception Invitation](#)

Controlled Release Society Annual Meeting & Exposition

July 16-19, 2017

Boston, MA

Booth #318

[Schedule a Meeting](#)

Discovery on Target

September 27-29, 2017

Boston, MA

Booth #408

[Schedule a Meeting](#)

Industry Insights

Qualification of Drug Development Tools: FDA Updates Process

Report: Oncology costs increasing faster than before

5 trends shaping rare disease drug development

China FDA changes will speed up approval process, says CRO

hello@bioduro.com | [+1 \(858\) 529-6600](tel:+18585296600) | www.bioduro.com

STAY CONNECTED:

